Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

<p><strong>Background:</strong><br /> Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrex...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Nash, P, Mease, PJ, Fleishaker, D, Wu, J, Coates, LC, Behrens, F, Gladman, DD, Kivitz, AJ, Wei, JC, Shirinsky, I, Menon, S, Romero, AB, Fallon, L, Hsu, MA, Wang, C, Kanik, KS
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Elsevier 2020

Những quyển sách tương tự

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Bằng: Nash, P, et al.
Được phát hành: (2021)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Bằng: Peter Nash, et al.
Được phát hành: (2020-06-01)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Bằng: Nash, P, et al.
Được phát hành: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
Bằng: Nash, P, et al.
Được phát hành: (2018)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Bằng: Alison O’Mahony, et al.
Được phát hành: (2018-06-01)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Bằng: Tsutomu Takeuchi, et al.
Được phát hành: (2021-08-01)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Bằng: Roy Fleischmann, et al.
Được phát hành: (2022-12-01)

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
Bằng: Nash, P, et al.
Được phát hành: (2020)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
Bằng: Mease, P, et al.
Được phát hành: (2018)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Bằng: Coates, L, et al.
Được phát hành: (2020)

Methotrexate in psoriasis and psoriatic arthritis
Bằng: Coates, L, et al.
Được phát hành: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Bằng: Gladman, DD, et al.
Được phát hành: (2022)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
Bằng: Helliwell, P, et al.
Được phát hành: (2018)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Bằng: Coates, L, et al.
Được phát hành: (2021)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Bằng: Nash, P, et al.
Được phát hành: (2018)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
Bằng: de Vlam, K, et al.
Được phát hành: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Bằng: Peter Nash, et al.
Được phát hành: (2018-11-01)

Precision drug delivery through methotrexate and tofacitinib citrate encapsulated mesoporous silica scaffold
Bằng: Dinesh Chakole, et al.
Được phát hành: (2024-06-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
Bằng: Dougados, M, et al.
Được phát hành: (2020)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Bằng: Dafna D. Gladman, et al.
Được phát hành: (2024-12-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Bằng: Dafna D. Gladman, et al.
Được phát hành: (2022-02-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Bằng: Philip J. Mease, et al.
Được phát hành: (2024-01-01)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
Bằng: Taylor, P, et al.
Được phát hành: (2019)

Psoriatic arthritis - Tofacitinib as a new treatment
Bằng: Marta Skorupska, et al.
Được phát hành: (2024-06-01)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Bằng: Alexis Ogdie, et al.
Được phát hành: (2024-09-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Bằng: Philip J Mease, et al.
Được phát hành: (2019-06-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
Bằng: Philip J. Mease, et al.
Được phát hành: (2023-08-01)

Fate of lymphocytes after withdrawal of tofacitinib treatment.
Bằng: Elisa Piscianz, et al.
Được phát hành: (2014-01-01)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
Bằng: Mease, PJ, et al.
Được phát hành: (2019)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
Bằng: Ana-Maria Orbai, et al.
Được phát hành: (2022-09-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Bằng: Dougados, M, et al.
Được phát hành: (2022)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Bằng: Adrian Ciurea, et al.
Được phát hành: (2023-09-01)

Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
Bằng: Yan Gao, et al.
Được phát hành: (2023-05-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Bằng: Maxime Dougados, et al.
Được phát hành: (2022-11-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Bằng: Laura C. Coates, et al.
Được phát hành: (2021-03-01)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
Bằng: Ogdie, A, et al.
Được phát hành: (2018)

Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
Bằng: Rattanakaemakorn P, et al.
Được phát hành: (2021-05-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Bằng: Lars E. Kristensen, et al.
Được phát hành: (2023-02-01)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Bằng: Philip J Mease, et al.
Được phát hành: (2019-06-01)

Tofacitinib
Bằng: Nilgün Şentürk
Được phát hành: (2022-04-01)